Fate Therapeutics, Inc.
FATEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fate Therapeutics, Inc. focuses on Biotechnology services and products. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. Valued at $297.2M, FATE is a micro-cap name in its sector. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Market Cap
$297.2M
Beta
2.55
P/E (TTM)
—
P/E (Fwd)
-2.56
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.97
ROE
-60.8%
ROA
-26.2%
Cash
$153.8M
Total Debt
$75.7M
Free CF
-$48.7M
52W Change
153.1%
Annual Financials
Cash vs Debt
Where FATE stands vs its 150-day and 200-day moving averages
As of the August 19, 2026 close, FATE finished 39.89% above its 150-day moving average ($1.83) and 56.10% above its 200-day moving average ($1.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FATE overbought or oversold?
At the August 19, 2026 close, FATE's RSI(14) was 58.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $153.8M in cash and $75.7M in debt, FATE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$48.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -60.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $96.3M (2022) to $6.6M (2025), a 93% decline worth watching.
A beta of 2.55 means FATE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Fate Therapeutics, Inc.'s trajectory.